Kevin Li is listed as a director on 15 SEC Form D filings by 5 issuers between Jul 2015 and Jul 2021: Neurelis, Inc. (San Diego, CA — biotechnology — 2015–2021; $114.8M reported sold to 26 investors), Qpex Biopharma, Inc. (San Diego, CA — biotechnology — 2018–2019; $27.4M reported sold to 11 investors), JumpCode Genomics, Inc. (San Diego, CA — biotechnology — 2020; $21M reported sold to 8 investors), Multiverse, Inc. (San Francisco, CA — other technology — 2021; $17.7M reported sold to 21 investors) and iGenomX International Genomics Corp (Carlsbad, CA — industry reported as "Other" — 2019; $3.02M reported sold to 17 investors).
What this means A repeat sponsor — 5 separate companies raised money with this person listed as director, over about 6 years. Across those companies the filings report $183.8M sold in total.
Listed alongside Craig C. Chambliss (8 shared filings), David F. Hale (8 shared filings), Priyanka Belawat (7 shared filings), George Stuart (6 shared filings), Cam L. Garner (4 shared filings) and 20 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Kevin. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 1 bankruptcy case matching the name listed in Key records below.
What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 15 public filings for Kevin Li and found 8 differences, 2 worth asking the sponsor about: Form D filed 175 days after the first sale; Form D filed 109 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.